On nearly every measure, startup companies punch above their weight in bringing life-changing drugs to market.
Prescription Drugs
All Prescription Drugs
By using a flawed measure of prescription drug costs, CMS failed to tackle high-priced medicines.
Under the new guidance, there is genuine potential to curtail outlandish drug prices. However, the new guidance carries some real risk for Medicare beneficiaries
Europe designates all biosimilars as interchangeable with original biologics. It’s time for the United States to do the same
Not all R&D spending by the pharmaceutical industry is equally productive. Small companies develop most new medicines.
The most consequential part of the decision memo clarified Medicaid's responsibilities in covering the drug
The FDA should approve more drugs faster, but we should stop forcing Medicare to pay for cost-ineffective drugs.
The FDA's standards for accelerated approval are only effective if they are enforced